Research programme: cancer vaccines - OncoTherapy Science/Otsuka Pharmaceuticals

Drug Profile

Research programme: cancer vaccines - OncoTherapy Science/Otsuka Pharmaceuticals

Latest Information Update: 22 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Otsuka Pharmaceutical
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Solid tumours

Most Recent Events

  • 30 Mar 2010 Preclinical development is ongoing in Japan
  • 12 Feb 2008 A peptide vaccine licensed to Otsuka Pharmaceuticals worldwide for the treatment of pancreatic cancer
  • 27 Nov 2007 Preclinical trials in Bladder cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top